Zoe E Brooks, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 608 Water Street, Union Mills, IN 46382 Phone: 219-688-7238 Fax: 219-512-9018 |
News Archive
IMRIS Inc. and MRI Interventions, Inc. today announced that Cook Children's Medical Center in Fort Worth, Texas, is the first U.S. pediatric hospital to offer asleep deep brain stimulation surgery to children suffering from dystonia by utilizing the combination of MRI Interventions' ClearPoint Neuro Intervention System and an IMRIS VISIUS Surgical Theatre for real-time intraoperative image guidance and procedure visualization.
Labopharm Inc. today announced it has provided YA Global Master SPV Ltd. with notice of its intention to draw down $1 million under its previously announced standby equity distribution agreement (SEDA). (All currency figures are in Canadian dollars.)
OriGene Technologies, Inc. has recently achieved a significant milestone in its quest for developing an assay for every human protein through the release of 1,500 mouse monoclonal antibodies under the TrueMAB brand. Each TrueMAB antibody is specifically developed with full-length human proteins produced in HEK293T cells and validated for critical research and diagnostic needs requiring improved antibody sensitivity and specificity.
A new procedure is now available for the treatment of chronic bowel incontinence, a disorder impacting the lives of more than 18 million Americans. The treatment, called InterStim Therapy is a minimally invasive procedure which uses electrical impulses to stimulate the sacral nerve and improve muscle function.
In five different studies presented at the American College of Gastroenterology's (ACG) 75th Annual Scientific meeting in San Antonio, researchers explored the impact of various factors on increasing rates of Clostridium difficile infection (C. difficile), such as the use of proton pump inhibitors (PPIs) and the substantial increase in antibiotic use due to new National Hospital Quality Measures; strategies to combat high rates of C. difficile infections; and cuttingâedge treatments for this potentially deadly-and quite common-infection.
› Verified 8 days ago